# Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation

> **NCT02196961** · PHASE2 · COMPLETED · sponsor: **Prof. Dr. med. Dirk Schadendorf** · enrollment: 180 (actual)

## Conditions studied

- Merkel Cell Carcinoma

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02196961
- **Lead sponsor:** Prof. Dr. med. Dirk Schadendorf
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2024-08-31
- **Final completion:** 2024-08-31
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2025-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02196961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02196961, "Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02196961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*